Radiation therapy is highly effective at killing cancer cells, but it often harms healthy skin around the treatment area, a common side effect experienced by up to 95% of cancer patients undergoing treatment. In worst-case scenarios, it can result in delayed or halted treatment.  

Researchers at Houston Methodist Research Institute have now discovered a promising new approach that can protect patients from radiation-induced skin damage during cancer treatment.  

In a significant breakthrough for cancer immunotherapy, collaborative studies published simultaneously in Immunity & Inflammation and Nature have demonstrated a critical molecular mechanism that drives CD8⁺ T cells into a dysfunctional “exhausted” state within tumors. The studies reveal how chronic antigen exposure opens a molecular switch—the suppression of the FOXO1-KLHL6 axis—to promote T cells toward exhaustion, providing a promising new target for intervention.

Researchers have proposed a method for ⁹⁹Mo production via electron accelerator irradiation of a natural-uranium-bearing liquid molten salt target. This approach offers significant advantages, including low nuclear proliferation risk, online extraction capability, and low construction costs. Consequently, it provides a viable pathway for stable, large-scale ⁹⁹Mo production.

UC San Diego researchers have harnessed the body's immune response to a common virus to shrink pancreatic tumors, offering hope for a new cancer treatment approach.

IRB Barcelona inaugurates the country’s first end-to-end fully integrated spatial omics platform, enabling scientists to map biological activity directly within its original tissue context.

The Institute has invested more than €3 million to equip the platform with the latest spatial transcriptomics and spatial proteomics technologies, along with advanced image analysis and bioinformatics capabilities.

This strategic initiative unites five specialised Core Facilities to create a coordinated, end-to-end workflow supporting research and innovation across academic, clinical, and industry partners in Spain and beyond.